Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07173075

Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly

This study aims to assess whether reduced muscle mass is associated with an increased risk of bleeding in the elderly receiving direct oral anticoagulant therapy.

The researchers will compare the muscle mass of patients who experienced a hemorrhage (case) with that of patients who did not (control).

Muscle mass is a key criterion in the assessment of sarcopenia and malnutrition, two conditions frequently associated with aging. Sarcopenia is characterized by a significant loss of muscle mass and strength, while malnutrition is an alteration of nutritional status, often accompanied by sarcopenia, weight loss or a low body mass index (BMI). So at the same time, we want to compare sarcopenia and malnutrition between the two groups (case and control).

Cases and controls will benefit from a consultation during which measurements will be taken: weight, height, BMI, calf circumference, impedancemetry, etc. A blood test will be taken to measure anti-Xa activity (drug activity) and any missing analyses.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

70 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CHU de Clermont-Ferrand

Clermont-Ferrand, 63000, France

Location contact

Julien Soret

PRINCIPAL_INVESTIGATOR

Lise laclautre

CONTACT

[email protected]

+334754963

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • age of at least 70 years
  • treated with one of the two factor Xa inhibitors used in France: Apixaban, Rivaroxaban.
  • For cases : hemorrhagic event causing hospitalization
  • For controls : free from hemorrhagic events.

Exclusion criteria

  • Failure to obtain a consent form
  • Patient under legal protection (guardianship, curatorship, or legal safeguard)
  • Recurrent bleeding from a pre-existing lesion that has not received specific treatment. For example: unexplored gastrointestinal bleeding, cutaneous bleeding from a cancerous wound with therapeutic abstention.
  • Bleeding caused by high-velocity trauma, surgery, or assault
  • Contraindications to impedance measurement: pacemaker, cardiac defibrillator
  • Elements that may provide erroneous impedance measurement data: bilateral limb amputation, bilateral joint replacements, dialysis.
  • Unable to maintain the supine position.
  • Digestive absorption disorder (celiac disease, short bowel, stoma, etc.)

Treatment and study plan

impedancemetry

Diagnostic Test

impedancemetry by the InBody S10 device, during a visit, after stabilization of the patient's blood volume, within a limit of 7 days after inclusion

Other names: bio-impedancemetry

Primary outcomes

  1. Muscle mass

    Time frame: from enrollment and within a limit of 7 days after inclusion.

    Appendicular muscle mass expressed in kg is measured by an InBody S10 impedance meter (Appendix 3: InBody S10 impedance meter), during a visit, after stabilization of the patient's blood volume, within a limit of 7 days after inclusion.

Secondary outcomes

  1. confirmed sarcopenia

    Time frame: from enrollment and within a limit of 7 days after inclusion.

    This is the combination of:

    • a "reduction in muscle strength" determined by a grip strength measurement and a Timed Chair Stand Test measurement
    • a "reduction in muscle mass", determined by the primary endpoint
  2. malnutrition

    Time frame: from enrollment and within a limit of 7 days after inclusion.

    According to the High Authority of Health, the diagnosis of malnutrition requires the presence of at least one phenotypic criterion and one etiological criterion.

    The phenotypic criteria are as follows (one criterion is sufficient):

    • Weight loss ≥ 5% in 1 month or ≥ 10% in 6 months or ≥ 10% compared to usual weight before the onset of the disease;
    • BMI < 22 kg/m²;
    • Confirmed sarcopenia

    The etiological criteria are as follows (one criterion is sufficient):

    • Reduction in food intake of ≥ 50% for more than 1 week, or any reduction in intake for more than 2 weeks compared to: usual food consumption or protein-energy requirements;
    • Reduced absorption (malabsorption/maldigestion);
    • Pathological situation (with or without inflammatory syndrome): acute pathology or chronic pathology or progressive malignant pathology.
  3. severe malnutrition

    Time frame: from enrollment and within a limit of 7 days after inclusion.

    According to the High Authority of Health, the criteria for severe malnutrition are as follows (one criterion is sufficient):

    • BMI < 20 kg/m²;
    • Weight loss: ≥ 10% in 1 month, or ≥ 15% in 6 months, or ≥ 15% compared to the usual weight before the onset of the disease;
    • Albumin level ≤ 30 g/L.
  4. severity of muscle mass reduction

    Time frame: from enrollment and within a limit of 7 days after inclusion.

    There is no definition expressing a threshold; we will consider that the lower the variation is from the median, the greater the loss of muscle mass.

Study contacts

Contact information is provided by the study sponsor or research team.

Lise laclautre

CONTACT

[email protected]

+33473754963

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Acronym: SARCORRHAGED

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Sep 15, 2025
Registry last updated
Sep 15, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.